PortalPublikationenBaseline Characteristics Predicting Very Good Outcome of All...

Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia - A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT

Standard

Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia - A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT. / van Gelder, Michel; Ziagkos, Dimitris; de Wreede, Liesbeth; van Biezen, Anja; Dreger, Peter; Gramatzki, Martin; Stelljes, Matthias; Andersen, Niels Smedegaard; Schaap, Nicolaas; Vitek, Antonin; Beelen, Dietrich; Lindström, Vesa; Finke, Jürgen; Passweg, Jacob; Eder, Matthias; Machaczka, Maciej; Delgado, Julio; Krüger, William; Raida, Luděk; Socié, Gerard; Jindra, Pavel; Afanasyev, Boris; Wagner, Eva; Chalandon, Yves; Henseler, Anja; Schoenland, Stefan; Kröger, Nicolaus; Schetelig, Johannes; CLL Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.

in: CL LYMPH MYELOM LEUK, Jahrgang 17, Nr. 10, 10.2017, S. 667-675.e2.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

van Gelder, M, Ziagkos, D, de Wreede, L, van Biezen, A, Dreger, P, Gramatzki, M, Stelljes, M, Andersen, NS, Schaap, N, Vitek, A, Beelen, D, Lindström, V, Finke, J, Passweg, J, Eder, M, Machaczka, M, Delgado, J, Krüger, W, Raida, L, Socié, G, Jindra, P, Afanasyev, B, Wagner, E, Chalandon, Y, Henseler, A, Schoenland, S, Kröger, N, Schetelig, J & CLL Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation 2017, 'Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia - A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT', CL LYMPH MYELOM LEUK, Jg. 17, Nr. 10, S. 667-675.e2. https://doi.org/10.1016/j.clml.2017.06.007

APA

van Gelder, M., Ziagkos, D., de Wreede, L., van Biezen, A., Dreger, P., Gramatzki, M., Stelljes, M., Andersen, N. S., Schaap, N., Vitek, A., Beelen, D., Lindström, V., Finke, J., Passweg, J., Eder, M., Machaczka, M., Delgado, J., Krüger, W., Raida, L., ... CLL Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation (2017). Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia - A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT. CL LYMPH MYELOM LEUK, 17(10), 667-675.e2. https://doi.org/10.1016/j.clml.2017.06.007

Vancouver

van Gelder M, Ziagkos D, de Wreede L, van Biezen A, Dreger P, Gramatzki M et al. Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia - A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT. CL LYMPH MYELOM LEUK. 2017 Okt;17(10):667-675.e2. https://doi.org/10.1016/j.clml.2017.06.007

Bibtex

@article{0785ce4b4f744de5b4098a6275cbb92b,
title = "Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia - A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT",
abstract = "BACKGROUND: Patients with genetically high-risk relapsed/refractory chronic lymphocytic leukemia have shorter median progression-free survival (PFS) with kinase- and BCL2-inhibitors (KI, BCL2i). Allogeneic hematopoietic stem cell transplantation (alloHCT) may result in sustained PFS, especially in younger patients because of its age-dependent non-relapse mortality (NRM) risk, but outcome data are lacking for this population.PATIENTS AND METHODS: Risk factors for 2-year NRM and 8-year PFS were identified in patients < 50 years in an updated European Society for Blood and Marrow Transplantation registry cohort (n = 197; median follow-up, 90.4 months) by Cox regression modeling, and predicted probabilities of NRM and PFS of 2 reference patients with favorable or unfavorable characteristics were plotted.RESULTS: Predictors for poor 8-year PFS were no remission at the time of alloHCT (hazard ratio [HR], 1.7; 95% confidence interval [CI], 1.1-2.5) and partially human leukocyte antigen (HLA)-mismatched unrelated donor (HR, 2.8; 95% CI, 1.5-5.2). The latter variable also predicted a higher risk of 2-year NRM (HR, 4.0; 95% CI, 1.4-11.6) compared with HLA-matched sibling donors. Predicted 2-year NRM and 8-year PFS of a high cytogenetic risk (del(17p) and/or del(11q)) patient in remission with a matched related donor were 12% (95% CI, 3%-22%) and 54% (95% CI, 38%-69%), and for an unresponsive patient with a female partially HLA-matched unrelated donor 37% (95% CI, 12%-62%) and 38% (95% CI, 13%-63%).CONCLUSION: Low predicted NRM and high 8-year PFS in favorable transplant high cytogenetic risk patients compares favorably with outcomes with KI or BCL2i. Taking into account the amount of uncertainty for predicting survival after alloHCT and after sequential administration of KI and BCL2i, alloHCT remains a valid option for younger patients with high cytogenetic risk chronic lymphocytic leukemia with a well-HLA-matched donor.",
keywords = "Journal Article",
author = "{van Gelder}, Michel and Dimitris Ziagkos and {de Wreede}, Liesbeth and {van Biezen}, Anja and Peter Dreger and Martin Gramatzki and Matthias Stelljes and Andersen, {Niels Smedegaard} and Nicolaas Schaap and Antonin Vitek and Dietrich Beelen and Vesa Lindstr{\"o}m and J{\"u}rgen Finke and Jacob Passweg and Matthias Eder and Maciej Machaczka and Julio Delgado and William Kr{\"u}ger and Lud{\v e}k Raida and Gerard Soci{\'e} and Pavel Jindra and Boris Afanasyev and Eva Wagner and Yves Chalandon and Anja Henseler and Stefan Schoenland and Nicolaus Kr{\"o}ger and Johannes Schetelig and {CLL Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation}",
note = "Copyright {\textcopyright} 2017 Elsevier Inc. All rights reserved.",
year = "2017",
month = oct,
doi = "10.1016/j.clml.2017.06.007",
language = "English",
volume = "17",
pages = "667--675.e2",
journal = "CL LYMPH MYELOM LEUK",
issn = "2152-2650",
publisher = "Cancer Media Group",
number = "10",

}

RIS

TY - JOUR

T1 - Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia - A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT

AU - van Gelder, Michel

AU - Ziagkos, Dimitris

AU - de Wreede, Liesbeth

AU - van Biezen, Anja

AU - Dreger, Peter

AU - Gramatzki, Martin

AU - Stelljes, Matthias

AU - Andersen, Niels Smedegaard

AU - Schaap, Nicolaas

AU - Vitek, Antonin

AU - Beelen, Dietrich

AU - Lindström, Vesa

AU - Finke, Jürgen

AU - Passweg, Jacob

AU - Eder, Matthias

AU - Machaczka, Maciej

AU - Delgado, Julio

AU - Krüger, William

AU - Raida, Luděk

AU - Socié, Gerard

AU - Jindra, Pavel

AU - Afanasyev, Boris

AU - Wagner, Eva

AU - Chalandon, Yves

AU - Henseler, Anja

AU - Schoenland, Stefan

AU - Kröger, Nicolaus

AU - Schetelig, Johannes

AU - CLL Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

N1 - Copyright © 2017 Elsevier Inc. All rights reserved.

PY - 2017/10

Y1 - 2017/10

N2 - BACKGROUND: Patients with genetically high-risk relapsed/refractory chronic lymphocytic leukemia have shorter median progression-free survival (PFS) with kinase- and BCL2-inhibitors (KI, BCL2i). Allogeneic hematopoietic stem cell transplantation (alloHCT) may result in sustained PFS, especially in younger patients because of its age-dependent non-relapse mortality (NRM) risk, but outcome data are lacking for this population.PATIENTS AND METHODS: Risk factors for 2-year NRM and 8-year PFS were identified in patients < 50 years in an updated European Society for Blood and Marrow Transplantation registry cohort (n = 197; median follow-up, 90.4 months) by Cox regression modeling, and predicted probabilities of NRM and PFS of 2 reference patients with favorable or unfavorable characteristics were plotted.RESULTS: Predictors for poor 8-year PFS were no remission at the time of alloHCT (hazard ratio [HR], 1.7; 95% confidence interval [CI], 1.1-2.5) and partially human leukocyte antigen (HLA)-mismatched unrelated donor (HR, 2.8; 95% CI, 1.5-5.2). The latter variable also predicted a higher risk of 2-year NRM (HR, 4.0; 95% CI, 1.4-11.6) compared with HLA-matched sibling donors. Predicted 2-year NRM and 8-year PFS of a high cytogenetic risk (del(17p) and/or del(11q)) patient in remission with a matched related donor were 12% (95% CI, 3%-22%) and 54% (95% CI, 38%-69%), and for an unresponsive patient with a female partially HLA-matched unrelated donor 37% (95% CI, 12%-62%) and 38% (95% CI, 13%-63%).CONCLUSION: Low predicted NRM and high 8-year PFS in favorable transplant high cytogenetic risk patients compares favorably with outcomes with KI or BCL2i. Taking into account the amount of uncertainty for predicting survival after alloHCT and after sequential administration of KI and BCL2i, alloHCT remains a valid option for younger patients with high cytogenetic risk chronic lymphocytic leukemia with a well-HLA-matched donor.

AB - BACKGROUND: Patients with genetically high-risk relapsed/refractory chronic lymphocytic leukemia have shorter median progression-free survival (PFS) with kinase- and BCL2-inhibitors (KI, BCL2i). Allogeneic hematopoietic stem cell transplantation (alloHCT) may result in sustained PFS, especially in younger patients because of its age-dependent non-relapse mortality (NRM) risk, but outcome data are lacking for this population.PATIENTS AND METHODS: Risk factors for 2-year NRM and 8-year PFS were identified in patients < 50 years in an updated European Society for Blood and Marrow Transplantation registry cohort (n = 197; median follow-up, 90.4 months) by Cox regression modeling, and predicted probabilities of NRM and PFS of 2 reference patients with favorable or unfavorable characteristics were plotted.RESULTS: Predictors for poor 8-year PFS were no remission at the time of alloHCT (hazard ratio [HR], 1.7; 95% confidence interval [CI], 1.1-2.5) and partially human leukocyte antigen (HLA)-mismatched unrelated donor (HR, 2.8; 95% CI, 1.5-5.2). The latter variable also predicted a higher risk of 2-year NRM (HR, 4.0; 95% CI, 1.4-11.6) compared with HLA-matched sibling donors. Predicted 2-year NRM and 8-year PFS of a high cytogenetic risk (del(17p) and/or del(11q)) patient in remission with a matched related donor were 12% (95% CI, 3%-22%) and 54% (95% CI, 38%-69%), and for an unresponsive patient with a female partially HLA-matched unrelated donor 37% (95% CI, 12%-62%) and 38% (95% CI, 13%-63%).CONCLUSION: Low predicted NRM and high 8-year PFS in favorable transplant high cytogenetic risk patients compares favorably with outcomes with KI or BCL2i. Taking into account the amount of uncertainty for predicting survival after alloHCT and after sequential administration of KI and BCL2i, alloHCT remains a valid option for younger patients with high cytogenetic risk chronic lymphocytic leukemia with a well-HLA-matched donor.

KW - Journal Article

U2 - 10.1016/j.clml.2017.06.007

DO - 10.1016/j.clml.2017.06.007

M3 - SCORING: Journal article

C2 - 28694085

VL - 17

SP - 667-675.e2

JO - CL LYMPH MYELOM LEUK

JF - CL LYMPH MYELOM LEUK

SN - 2152-2650

IS - 10

ER -